HQL

abrdn Life Sciences Investors

HQL

Market cap $407M

Overview Fund Activity

14.11 USD

+0.16

1.15%

At close Updated Sep 18, 3:59 PM EDT

1 day

1.15%

5 days

-1.33%

1 month

0.93%

3 months

11.9%

6 months

8.12%

Year to date

6.65%

1 year

-8.14%

5 years

-20.46%

10 years

-49.79%

About: abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.

Financials Asset Management

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 13

4% more capital invested

Capital invested by funds: $113M [Q1] → $117M (+$4.55M) [Q2]

0.77% less ownership

Funds ownership: 32.44% [Q1] → 31.67% (-0.77%) [Q2]

9% less funds holding

Funds holding: 81 [Q1] → 74 (-7) [Q2]

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

See Fund Rankings

Financial journalist opinion

HQL: We Should Be Accumulating During The Weakness

HQL offers a high 12% yield and trades at a discount, making it attractive for income-focused investors seeking healthcare sector exposure. The fund is heavily weighted in biotechnology, leading to underperformance versus broader healthcare ETFs and higher sensitivity to sector weakness. Dividend coverage remains consistent despite recent earnings volatility, but distributions are not tax-efficient and rely on capital gains.

HQL: We Should Be Accumulating During The Weakness

ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS

PHILADELPHIA , Aug. 11, 2025 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF, VFL), announced today that the closed end funds in the chart directly below will pay the distributions indicated on a per share basis on August 29, 2025 to all shareholders of record as of August 22, 2025 (ex-dividend date August 22, 2025). These dates apply to the Funds listed below with the exception of the abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN) which will pay on September 30, 2025, to all shareholders of record as of August 22, 2025 (ex-dividend date August 22, 2025).

ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS

ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS

PHILADELPHIA , June 30, 2025 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on June 30, 2025, on a per share basis to all shareholders of record as of June 23, 2025 (ex-dividend date June 23, 2025). These dates apply to the Funds listed below with the exception of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund Inc. (IFN) which paid on June 30, 2025, to all shareholders of record as of May 22, 2025 (ex-dividend date May 22, 2025).

ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS

CEF Insights: The Future Of Healthcare Investing

Groundbreaking AI-powered initiatives are set to transform the healthcare landscape, potentially revolutionizing cancer research and healthcare investing. Aberdeen Investments' four healthcare-focused closed-end funds meet various investor needs: THQ/THW for income and stability, HQH/HQL for growth and innovation exposure. Jason Akus, Portfolio Manager and Head of Healthcare Investments with Aberdeen Investments, gives insight into how new innovations may impact investment opportunities.

CEF Insights: The Future Of Healthcare Investing

HQL: Positive Outlook Due To Increased Healthcare Spending

I maintain my buy rating on HQL due to its attractive 14% yield, discounted valuation, and long-term healthcare growth outlook. Despite recent NAV declines and inconsistent income, HQL's performance is tied to macro conditions, not internal flaws, and should improve as the sector rebounds. HQL's diversified biotech-heavy portfolio, lack of leverage, and simple strategy offer stability and upside as healthcare spending rises.

HQL: Positive Outlook Due To Increased Healthcare Spending

The Motley Fool

These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount

My definition of a high yield is any yield at least twice the level of the S&P 500's yield. The threshold is currently around 2.56%.

These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount

5 Best CEFs This Month For Yields Up To 14%

For income investors, closed-end funds remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. Closed-end funds, or CEFs, are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer "excess" discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.

5 Best CEFs This Month For Yields Up To 14%

HQL: Attractive Valuation, Aligned To Benefit From Aging Gen X

HQL: Attractive Valuation, Aligned To Benefit From Aging Gen X

HQL: Attractive Valuation, Aligned To Benefit From Aging Gen X

5 Best CEFs This Month For Nearly 10% Yield (January 2025)

For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.

5 Best CEFs This Month For Nearly 10% Yield (January 2025)

Aberdeen Or 'abrdn' - Either Way The Coverage Looks A Bit Thin

Closed-end funds offer unique advantages, like buying at discounts and leveraging with institutionally priced debt, making them ideal income-generating vehicles. Cash distributions are key contributors to total return, but it is essential to be sure they are actually covered by fund earnings. Some investors overly prioritize distribution yields, neglecting the importance of considering total return as a whole.

Aberdeen Or 'abrdn' - Either Way The Coverage Looks A Bit Thin

See News Rankings

Charts implemented using Lightweight Charts™